What question did this study set out to answer?

To compare the diagnostic performance of the synthetic amino acid radiotracer anti-3-18F-FACBC PET/CT against 111In-capromab pendetide SPECT/CT in detecting recurrent prostate cancer.

April 15, 2011Radiology

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

View Full Paper

Ask AI

Bookmark

Authors

DSDavid M. SchusterEmory University BSBital Savir-BaruchAlbert Einstein College of Medicine PNPeter T. NiehEmory University

Discussion

Member takes

Implication

Prospective study demonstrates superior sensitivity of anti-18F-FACBC PET/CT over 111In-capromab pendetide SPECT/CT in recurrent prostate carcinoma, indicating improved detection of metastases.

Key Points

To compare the diagnostic performance of the synthetic amino acid radiotracer anti-3-18F-FACBC PET/CT against 111In-capromab pendetide SPECT/CT in detecting recurrent prostate cancer.
Prospective comparative imaging study of 50 patients (mean age 68.3 ± 8.1 years) with suspected recurrent prostate carcinoma following definitive therapy and negative bone scans.
Patients underwent both anti-3-18F-FACBC PET/CT and 111In-capromab pendetide SPECT/CT within 6 weeks of each other.
Scans were evaluated by two interpreters for uptake in the prostate bed and extraprostatic regions against a composite reference standard of tissue, imaging, laboratory, and clinical data.
For prostate bed recurrence, anti-3-18F-FACBC achieved a sensitivity of 89% (32/36; 95% CI: 74%, 97%), specificity of 67% (8/12; 95% CI: 35%, 90%), and accuracy of 83% (40/48; 95% CI: 70%, 93%), compared with 69% sensitivity (25/36; 95% CI: 52%, 84%), 58% specificity (7/12; 95% CI: 28%, 85%), and 67% accuracy (32/48; 95% CI: 52%, 80%) for 111In-capromab pendetide.
For extraprostatic recurrence, anti-3-18F-FACBC yielded a sensitivity of 100% (10/10; 95% CI: 69%, 100%), specificity of 100% (7/7; 95% CI: 59%, 100%), and accuracy of 100% (17/17; 95% CI: 80%, 100%), whereas 111In-capromab pendetide showed a sensitivity of 10% (1/10; 95% CI: 0%, 45%), specificity of 100% (7/7; 95% CI: 59%, 100%), and accuracy of 47% (8/17; 95% CI: 23%, 72%).

Cite This Study

Schuster et al. (2011) studied this question.

synapsesocial.com/papers/6a78d0ca9fd4195bcd5ac589 https://doi.org/10.1148/radiol.11102023

View Full Paper

Ask AI

Bookmark

Implication

Prospective study demonstrates superior sensitivity of anti-18F-FACBC PET/CT over 111In-capromab pendetide SPECT/CT in recurrent prostate carcinoma, indicating improved detection of metastases.

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Discussion

Member takes

Implication

Key Points

Cite This Study

Detection of Recurrent Prostate Carcinoma withanti-1-Amino-3-¹⁸F-Fluorocyclobutane-1-Carboxylic Acid PET/CT and¹¹¹In–Capromab Pendetide SPECT/CT

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider